Indoleamine 2,3 Dioxygenase 1 Market Share 2021 Growth Challenges, Opportunities and Future Trends 2027
The global indoleamine 2,3 dioxygenase 1 market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Indoleamine 2,3-dioxygenase 1 (IDO1) is the first and rate-limiting enzyme of tryptophan catabolism through the kynurenine pathway. It is an important molecule in the mechanisms of tolerance. Furthermore, its physiological function suppresses the potentially dangerous inflammatory processes in the body. The major factor driving the growth of the market is the increasing prevalence of cancer across the globe.
Moreover, IDO1 inhibitors are
used alone or in combination with immunotherapy, chemotherapy, adoptive
transfer, COX-2 inhibitors, membrane-associated PGE2 synthase inhibitors,
competitive antagonists and PI3K inhibitors among others to improve the
inhibition of local immunosuppression around tumor tissues as well as to
enhance tumor eradication. Furthermore, the combination of IFN-? treatment with
IDO1 inhibitors is a new cancer immunotherapeutic strategy to effectively
enhance antitumor immunity and eliminate TRCs.
To Request a Sample of our Report on Indoleamine 2,3
Dioxygenase 1 Market: https://www.omrglobal.com/request-sample/indoleamine-2-3-dioxygenase-1-market
Some major players in the market include Bristol-Myers
Squibb Company, and Merck KGaA, among others . The market players are
contributing significantly to the growth of the market by the adoption of
various strategies including mergers & acquisitions, geographical
expansion, partnerships and collaborations, and new product launches, to stay
competitive in the market. For instance, in January 2021, IO Biotech announced
that it has raised $155 million in a Series B financing round to fund the
clinical development of immune-modulating IDO and PD-L1 cancer vaccines. The
company showed that combining its IDO and PD-L1 vaccines with Opdivo triggered
complete responses in 45% of stage 4 melanoma patients.
Market Coverage
• The
market number available for – 2020-2027
• Base
year- 2020
• Forecast
period- 2021-2027
Segment Covered-
·
By Type
·
By Application
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape-
Bristol-Myers Squibb Company, and Merck KGaA, among others
(Get 15% Discount on Buying this Report)
A
full Report of Indoleamine 2,3 Dioxygenase 1 Market is Available @ https://www.omrglobal.com/industry-reports/indoleamine-2-3-dioxygenase-1-market
Global Indoleamine 2,3 Dioxygenase 1 Market Report by
Segment
By Type
• BMS-986205
• Dcellvax
• Epacadostat
• F-001287
• Galanal
• Others
By Application
• Alopecia
• Cervical
Cancer
• Gastric
Cancer
• Glioma
• Others
Global Indoleamine 2,3 Dioxygenase 1 Market Report by
Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment